Lipoprotein(a): Role in atherosclerosis and new treatment options

Area of Science:

• Cardiology
• Biochemistry
• Genetics

Background:

• Atherosclerosis involves inflammation and lipid accumulation in blood vessel walls, leading to narrowing.
• Dyslipidemia treatment aims to reduce atherosclerotic disease and major adverse cardiovascular events (MACE).
• Lipoprotein(a) (Lp(a)) is a key causal factor for cardiovascular (CV) events, independent of low-density lipoprotein (LDL) cholesterol levels.

Purpose of the Study:

• To review the role of lipoprotein(a) (Lp(a)) in cardiovascular risk.
• To assess the current evidence for treatments targeting high Lp(a) levels.
• To highlight the need for further research on the CV outcomes of Lp(a)-lowering therapies.

Main Methods:

• Literature review of studies on Lp(a) and cardiovascular risk.
• Analysis of existing data on hypolipidemic agents and their effect on Lp(a).
• Evaluation of the evidence from randomized controlled trials regarding CV outcomes.

Main Results:

• Lp(a) levels are genetically determined and contribute to plaque formation, thrombogenicity, and inflammation.
• Elevated Lp(a) (above 75th percentile) is linked to reduced risk of aortic valve stenosis and myocardial infarction, but higher levels (above 90th percentile) increase heart failure risk.
• No hypolipidemic agents are specifically approved for high Lp(a); current treatments' CV benefits require more robust evidence from ongoing trials.

Conclusions:

• Lipoprotein(a) (Lp(a)) represents a significant, genetically determined cardiovascular risk factor.
• While some treatments can lower Lp(a), their efficacy in preventing major adverse cardiovascular events (MACE) needs further validation through extensive clinical trials.
• Ongoing research is crucial to establish definitive treatment guidelines for individuals with elevated Lp(a) levels and high cardiovascular risk.